Sero-388 -

“If we give this to everyone, who will be left to mourn the loss?”

In the annals of neuropsychopharmacology, most compounds are given names that sound like filing cabinet coordinates. But SERO-388 is different. To the small, clandestine community of neurohackers, bioethicists, and trauma researchers, it is known by a darker moniker: The Ego-Soluble.

And that is the point.

Most users return to baseline within six hours. But a significant subset—approximately 7.4% in the leaked Phase Ib data—develop what clinicians now call . They wake up the next day and the narrative self does not reboot. It’s not that they’ve lost memories. They remember their name, their history, their attachments. But those memories feel as compelling as a grocery list from a decade ago. The emotional gravity of being them never returns.

SERO-388. The ego’s last enemy. The silence at the end of the internal monologue. Take it if you dare—but understand: the person who decides to take it will not be the one who returns. sero-388

For three hours, Elias existed as pure phenomenal consciousness—sight, sound, proprioception, all streaming without an owner. He reported no fear. Not because he was brave, but because fear requires a self to be threatened. There was no self to protect.

The first human trial, conducted off-book in a Zurich bunker, involved a former Zen monk turned quantitative analyst. His name was Elias. Forty minutes post-administration, he was asked: “How do you feel?” “If we give this to everyone, who will

Proponents argue it could cure treatment-resistant depression, PTSD, and borderline personality disorder, all of which are diseases of a toxic self-narrative. “Kill the storyteller,” they say, “and the story can’t hurt you.”